Carregant...
Antibodies and Tyrosine Kinase Inhibitors in Breast Cancer Therapies
In recent years, new classes of molecules have been established as opportunities for the treatment of breast cancer. The approval of trastuzumab, the antibody against Her2/neu, in the late 1990s was followed by the approval of the antiangiogenic antibody bevacizumab in 2007. Progress in the understa...
Guardat en:
| Autors principals: | , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
S. Karger GmbH
2009
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2942015/ https://ncbi.nlm.nih.gov/pubmed/21160542 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000190063 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|